In this interview with Andrew Kleuss on Investors Hub, Vitaliy makes the case that concerns over Amazon’s entry into the pharmaceuticals business are probably overblown. To parse this problem, Vitaliy differentiates between pharmacies and drug distributors, and analyzes the extent to which Amazon can compete with both. While Amazon might place some pressure on pharmacies over time, he explains how drug distributors’ unique supply chains should remain robust against a competitive threat from Amazon.
Enjoyed this read?
Share it with someone who’d love it too!
New to investing?
Explore these valuable guides to get started.
Related Articles

Current Thoughts on Tesla – Ep 254
📩 Join 94,000+ readers on my FREE weekly email newsletter: The EV Industry Landscape article: https://investor.fm/the-ev-industry-landscape/ 📚 Get my books: Soul in the Game - The Little Book of Sideways Markets - Active...

Europe Can’t Hide Behind America Anymore – Ep 253
📩 Join 94,000+ readers on my FREE weekly email newsletter: 📚 Get my books: Soul in the Game - The Little Book of Sideways Markets - Active Value Investing - WHO AM I: Vitaliy Katsenelson is the CEO of...

The Reputational Bankruptcy of the American Dollar – Ep 252
📩 Join 94,000+ readers on my FREE weekly email newsletter: 📚 Get my books: Soul in the Game - The Little Book of Sideways Markets - Active Value Investing - WHO AM I: Vitaliy Katsenelson is the CEO of...

Tariffs, Debt, and a Recession by Design – Ep 251
📩 Join 94,000+ readers on my FREE weekly email newsletter: 📚 Get my books: Soul in the Game - The Little Book of Sideways Markets - Active Value Investing - WHO AM I: Vitaliy Katsenelson is the CEO of...
0 comments